Transplantation, AutologousHematopoietic Stem Cell TransplantationMelphalanStem Cell TransplantationCombined Modality TherapyAntineoplastic Combined Chemotherapy ProtocolsMultiple MyelomaPeripheral Blood Stem Cell TransplantationTransplantation ConditioningTransplantation, HomologousTreatment OutcomeCyclophosphamideDisease-Free SurvivalRemission InductionSalvage TherapyEtoposideHodgkin DiseaseStem CellsVincristineSurvival RateMyeloablative AgonistsLymphoma, Non-HodgkinCytarabineCarmustineHematopoietic Stem Cell MobilizationRecurrenceSurvival AnalysisDoxorubicinBone Marrow TransplantationThiotepaGraft vs Host DiseaseAntineoplastic Agents, AlkylatingBone Marrow PurgingPrognosisHematologic NeoplasmsAntineoplastic AgentsWhole-Body IrradiationAmyloidosisRetrospective StudiesChemotherapy, AdjuvantBusulfanLymphoma, Mantle-CellAntibodies, Monoclonal, Murine-DerivedFollow-Up StudiesDexamethasoneBoronic AcidsHematopoietic Stem CellsPyrazinesPrednisoneCisplatinGranulocyte Colony-Stimulating FactorGraft SurvivalIfosfamideThalidomideAntigens, CD34Lymphoma, FollicularTime FactorsInduction ChemotherapyAutograftsLymphoma, T-Cell, PeripheralLiver TransplantationLymphoma, Large B-Cell, DiffuseLeukapheresisLymphomaCarboplatinPodophyllotoxinMesenchymal Stem Cell TransplantationMaintenance ChemotherapyNeoplasm, ResidualLeukemia, Myeloid, AcuteTransplantation ChimeraNeoplasm Recurrence, LocalDrug Administration ScheduleProspective StudiesNeoplasm StagingAntibodies, MonoclonalMitoxantroneBreast NeoplasmsCell TransplantationTissue DonorsCord Blood Stem Cell TransplantationLymphoma, B-CellMyelodysplastic SyndromesIdarubicinBleomycinNeoplasms, Second PrimaryKidney TransplantationBlood Transfusion, AutologousLeukemia, Plasma CellEnteropathy-Associated T-Cell LymphomaEmbryonic Stem CellsMethotrexateFeasibility StudiesNeutropeniaBlood Component RemovalImmunosuppressive AgentsInfusions, SpinalClinical Trials as TopicKaplan-Meier EstimateNeoplasms